 产品搜索 |
| 产品类别 |
| 推荐产品 |
 叔丁基二甲基氯硅烷 |
| 2-氯-4,6-二甲基吡啶 |
| 2-溴-4,6-二甲基吡啶 |
| 6-氯苯并三氮唑-1,1,3,3- |
| 1,3-二苯基异苯并呋喃 |
| 培哚普利 |
| 9-(4-乙酰氧基-3-乙酰氧 |
| 嘧啶-5-硼酸 |
| 2-氯-3-硝基-4-甲基吡啶 |
| 7-氮杂吲哚 |
| 4-氮杂吲哚 |
| 5-氮杂吲哚 |
| 6-氮杂吲哚 |
| 7-azaoxindole |
| 6-azaoxindole |
| 4-叔丁基苯硼酸 |
| D-氨基半乳糖盐酸盐 |
| N-乙酰基-D-氨基半乳糖 |
| 溴代葡萄糖苷 |
| 利培酮 |
| N-三氟乙酰基-L-赖氨酸 |
| N2-(1-乙氧羰基-3-苯丙基 |
| N2-[1-(S)-乙氧羰基-3-苯 |
| 3-氨基甲酰基苯硼酸 |
| 2,4-二氯-6-甲基嘧啶 |
| N-(4-氨基丁基)-N-乙基异 |
| AOP |
| BOP |
| 4,4-二甲氧基三苯甲基 |
| 2-氯-1-甲基吡啶碘盐 |
| HOTT |
| TSTU |
| 1-(4-甲磺基)-3-硝基-1,2,4 |
| TPTU |
| 2,4,6-三异丙基苯磺酰氯 |
| TOTU |
| TOTT |
| TNTU |
| TFFH |
| TDBTU |
| TCTU |
| TCFH |
| TBTU |
| TATU |
| N-Hydroxysulfosuccinimide sodi |
| 8-喹啉磺酰氯 |
| PyCloP |
| PYCLU |
| PyBroP |
| PyBOP |
|
| 产品展示 |
| 产品编号 |
产品名称 |
CAS No. |
含量 |
| W723631 | [3-(4-chlorophenyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]acetic acid | 1228650-22-3 | 95% |
| W723632 | ethyl N-({2-[(4-chlorophenyl)carbonyl]hydrazinyl}carbonyl)glycinate | 1228650-21-2 | 95% |
| W723633 | 2-(chloromethyl)-5-(2-chloro-phenyl)-1,3,4-oxadiazole | 24023-72-1 | 95% |
| W723634 | 5-bromo-N,N-dimethyl-2,3-dihydro-1-benzofuran-2-carboxamide | 1614233-62-3 | 95% |
| W723635 | N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1-benzofuran-2-carboxamide | 1614233-63-4 | 95% |
| W723636 | 6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine | 1614233-64-5 | 95% |
| W723637 | 6-(3,5-dimethoxyphenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine | 1614233-65-6 | 95% |
| W723638 | 6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine | 1614233-66-7 | 95% |
| W723639 | 6-(2,6-dichloro-3,5-dimethoxyphenyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidine | 1614233-67-8 | 95% |
| W723640 | N,N-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chromane-2-carboxamide | 1614233-68-9 | 95% |
| W723641 | 1-[(5-bromo-2,3-dihydro-1-benzofuran-2-yl)carbonyl]-4-methylpiperazine | 1614233-74-7 | 95% |
| W723642 | 1-methyl-4-{[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1-benzofuran-2-yl]carbonyl}piperazine | 1614233-75-8 | 95% |
| W723643 | 6-[6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-3,4-dihydroisoquinolin-1(2H)-one | 1614232-57-3 | 95% |
| W723644 | 6-(3,5-dimethoxyphenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine | 1614233-84-9 | 95% |
| W723645 | 6-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine | 1614233-85-0 | 95% |
| W723646 | 6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridine | 1614233-86-1 | 95% |
| W723647 | 6-(2,6-dichloro-3,5-dimethoxyphenyl)-3-iodo-1H-pyrazolo[4,3-c]pyridine | 1614233-87-2 | 95% |
| W723648 | 2-(4-bromo-2-methylphenoxy)-N,N-dimethylacetamide | 1030506-48-9 | 95% |
| W723649 | N,N-dimethyl-2-[2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]acetamide | 1614233-88-3 | 95% |
| W723650 | 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propanenitrile | 1612174-34-1 | 95% |
| W723651 | 6-(3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridine | 1614233-96-3 | 95% |
| W723652 | 6-(3,5-dimethoxyphenyl)-3-iodo-1H-pyrazolo[4,3-c]pyridine | 1614233-97-4 | 95% |
| W723653 | 6-(3,5-dimethoxyphenyl)-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine | 1614233-98-5 | 95% |
| W723654 | 2-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one | 1614234-01-3 | 95% |
| W723655 | 2-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one | 1614234-02-4 | 95% |
| W723656 | 3-bromo-6-ethyl-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one | 1614234-03-5 | 95% |
| W723657 | (6-ethyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)boronic acid | 1614234-04-6 | 95% |
| W723658 | 2-(2-methoxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one | 1614234-05-7 | 95% |
| W723659 | 2-(tetrahydro-2H-pyran-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one | 1614234-07-9 | 95% |
| W723660 | 2-(2-hydroxy-1-methylethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one | 1614234-09-1 | 95% |
|
|
|
|
